Flavor of the week: antibiotics

Share this article:

AstraZeneca and Roche each entered collaborations to take on hospital infections.

As noted by PMLive, AstraZeneca's collaboration with the Agency for Science, Technology and Research to attack gram-negative infections appears somewhat at odds with the drugmaker's decision to scale back its infection R&D.

Roche announced Monday that it is pursuing antibiotic research with private drugmaker Polyphor, with which it will target pseudomonas aeruginosa, an infection which the companies say accounts for 10% of US hospital-acquired infections.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions